(Reuters) - U.S. cancer drug maker Medivation Inc (O:MDVN) has decided to explore a sale following a $9.3 billion (6 billion pounds) acquisition offer from France's Sanofi SA (PA:SASY) and interest from other companies, people familiar with the matter said on Monday.
Pfizer Inc (N:PFE) and Amgen Inc (O:AMGN) are among the companies that have signed non-disclosure agreements with Medivation, which allow them to obtain confidential information about the company, the people said.
Sanofi made its bid for Medivation public on April 28, complaining that the San Francisco-based company was refusing to engage in negotiations. There is still no certainty that Sanofi's competitors will press ahead with bids for Medivation, the people cautioned.
The sources asked not to be identified because the deliberations are confidential. Medivation, Sanofi, Pfizer and Amgen declined to comment.